A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac in Health Adults Aged 26-45 Years
Latest Information Update: 15 Apr 2022
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
Most Recent Events
- 12 Apr 2022 Status changed from active, no longer recruiting to completed.
- 27 May 2021 Planned End Date changed from 30 Sep 2021 to 30 Nov 2021.
- 27 May 2021 Planned primary completion date changed from 30 Sep 2021 to 30 Jul 2021.